3,6-二氢-2H-吡喃-4-甲腈 | 105772-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 中文名称: 3,6-二氢-2H-吡喃-4-甲腈
• 中文别名: 3,6-二氢-2H-吡喃-4-氰基
• 英文名称: 3,6-dihydro-2H-pyran-4-carbonitrile
• 英文别名: 3,6-Dihydro-2H-pyran-4-carbonitrile
• CAS: 105772-13-2
• 化学式: C₆H₇NO
• 分子量: 109.128
• InChiKey: MICNNRIXWURVND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 包装等级：
  III
• 危险类别：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险品运输编号：
  1993
• 危险性描述：
  H225,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,6-Dihydro-2H-pyran-4-carbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,6-Dihydro-2H-pyran-4-carbonitrile
CAS number: 105772-13-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7NO
Molecular weight: 109.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,6-二氢-2H-吡喃-4-甲腈 在 N,N-diethylaniline borane 、 (1R,2S)-1-氨基-2-茚醇 、 二异丁基氢化铝 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 L-脯氨酸 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 甲醇 、 溶剂黄146 、 甲苯 为溶剂， 反应 7.0h， 生成 methyl (S)-4-(3,6-dihydro-2H-pyran-4-yl)-5-hydroxy-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinoline-3-carboxylate
  参考文献：
  名称：

  高效进入多环胆固醇酯转移蛋白抑制剂的实用对映选择性合成方法。

  摘要：

  已经开发了手性多环胆固醇酯转移蛋白（CETP）抑制剂1的有效对映选择性合成。通过开发改良的Hantzsch型反应以制备位阻吡啶环，利用新型BIBOP-氨基吡啶衍生的Ru配合物对位酮6进行对映选择性氢化，有效的ICl促进内酯形成，以及通过合成IHC促进内酯的形成，使该合成大规模可行。BF 3介导的氢化过程，用于非对映选择性的乳糖醇还原。这种有效的途径已成功扩展规模，以产生具有挑战性的CETP候选药物1的多千克数量。

  DOI：

  10.1021/ol501833g
• 作为产物：
  描述：

  四氢-4-羟基-2H-吡喃-4-甲腈 在 吡啶 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 生成 3,6-二氢-2H-吡喃-4-甲腈
  参考文献：
  名称：

  高效进入多环胆固醇酯转移蛋白抑制剂的实用对映选择性合成方法。

  摘要：

  已经开发了手性多环胆固醇酯转移蛋白（CETP）抑制剂1的有效对映选择性合成。通过开发改良的Hantzsch型反应以制备位阻吡啶环，利用新型BIBOP-氨基吡啶衍生的Ru配合物对位酮6进行对映选择性氢化，有效的ICl促进内酯形成，以及通过合成IHC促进内酯的形成，使该合成大规模可行。BF 3介导的氢化过程，用于非对映选择性的乳糖醇还原。这种有效的途径已成功扩展规模，以产生具有挑战性的CETP候选药物1的多千克数量。

  DOI：

  10.1021/ol501833g

文献信息

• [EN] SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF<br/>[FR] DIPYRIDYLAMINES SUBSTITUÉES ET LEURS UTILISATIONS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013174780A1

  公开（公告）日：2013-11-28

  The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.

  本发明提供了公式I的化合物及其各种实施方式，以及包含公式I的化合物及其各种实施方式的组合物。在公式I的化合物中，基团R1、R2、R3、R4、R5、R6、m、n和C-连接环具有如本文所述的含义。本发明还提供了使用公式I的化合物和包含公式I的化合物作为DLK抑制剂以及用于治疗神经退行性疾病和紊乱的方法。
• [EN] FACTOR XIIA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR XIIA
  申请人：UNIV LEEDS INNOVATIONS LTD

  公开号：WO2019186164A1

  公开（公告）日：2019-10-03

  This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

  本发明涉及公式(I)的化合物以及使用这些化合物进行治疗的方法。该发明还涉及用于生产该发明化合物的过程和方法。该发明化合物是凝血因子XII（例如凝血因子XIIa）的调节剂。具体来说，这些化合物是凝血因子XIIa的抑制剂，可能作为抗凝血剂有用。
• The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties
  作者：Tony Siu、Jason Brubaker、Peter Fuller、Luis Torres、Hongbo Zeng、Joshua Close、Dawn M. Mampreian、Feng Shi、Duan Liu、Xavier Fradera、Kevin Johnson、Nathan Bays、Elma Kadic、Fang He、Peter Goldenblatt、Lynsey Shaffer、Sangita B. Patel、Charles A. Lesburg、Carla Alpert、Lauren Dorosh、Sujal V. Deshmukh、Hongshi Yu、Joel Klappenbach、Fiona Elwood、Christopher J. Dinsmore、Rafael Fernandez、Lily Moy、Jonathan R. Young

  DOI：10.1021/acs.jmedchem.7b01135

  日期：2017.12.14

  lipophilic ligand efficiency as a key metric to track changes in the physicochemical properties of our analogs, which led to improvements in overall compound quality. In parallel, structural information guided advancements in JAK1 selectivity by informing on new vector space, which enabled the discovery of a unique key amino acid difference between JAK1 (Glu966) and JAK2 (Asp939). This difference was

  描述了一种适用于临床评估的有效的选择性低剂量Janus激酶1（JAK1）抑制剂的发现。作为将剂量降至最低的总体目标的一部分，我们奉行了一种药物化学策略，其重点是优化影响剂量大小（包括降低人体内C1代谢）的关键参数。并提高内在效力，生物利用度和溶解度。为了同时影响这些多个参数，我们使用亲脂性配体效率作为跟踪类似物理化性质变化的关键指标，从而改善了整体化合物的质量。同时，结构信息通过通知新的载体空间来指导JAK1选择性的发展，从而发现了JAK1（Glu966）和JAK2（Asp939）之间唯一的关键氨基酸差异。利用这种差异来始终如一地生产出具有JAK1选择性，功效和预计的人剂量最佳平衡的类似物，最终导致化合物28的发现。
• Bicyclic Pyrrolidines for Medicinal Chemistry via [3 + 2]-Cycloaddition
  作者：Vladimir I. Savych、Vladimir L. Mykhalchuk、Pavlo V. Melnychuk、Andrii O. Isakov、Taras Savchuk、Vadim M. Timoshenko、Sergiy A. Siry、Sergiy O. Pavlenko、Dmytro V. Kovalenko、Oleksandr V. Hryshchuk、Vitalii A. Reznik、Bohdan A. Chalyk、Vladimir S. Yarmolchuk、Eduard B. Rusanov、Pavel K. Mykhailiuk

  DOI：10.1021/acs.joc.1c01327

  日期：2021.10.1

  A general approach to bicyclic fused pyrrolidines via [3 + 2]-cycloaddition between nonstabilized azomethyne ylide and endocyclic electron-deficient alkenes was elaborated. “Push–pull” alkenes and CF3-alkenes did not react with the azomethyne ylide under the previously reported conditions, and we developed a superior protocol (LiF, 140 °C, no solvent). Among obtained products were medchem-relevant

  详细阐述了通过不稳定的偶氮甲炔叶立德和环内缺电子烯烃之间的 [3 + 2]-环加成来制备双环稠合吡咯烷的一般方法。在先前报道的条件下，“推拉”烯烃和 CF 3 -烯烃不与偶氮甲炔叶立德反应，我们开发了一种优越的方案（LiF，140 °C，无溶剂）。获得的产品包括与医药相关的双环砜、单氟、二氟和三氟甲基取代的吡咯烷。这种方法不仅允许制备新分子，而且显着简化了现有分子（例如，sofnicline）的合成。
• [EN] N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] N-(2-CYANO-HÉTÉROCYCLYL)PYRAZOLO-PYRIDONES EN TANT QU'INHIBITEURS DE LA JANUS KINASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014146492A1

  公开（公告）日：2014-09-25

  Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.

  提供了公式I的化合物，一种JAK抑制剂，以及其在治疗JAK介导疾病中的应用。